On July 19, 2019, the U.S. Food and Drug Administration approved multiple applications for generics of Lyrica (pregabalin). Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research noted that “approval of the first generics for pregabalin…is another example of the FDA’s longstanding commitment to advance patient access to lower-cost, high-quality medicines.”
Red Book pricing for pregabalin has now further reduced to as low as $.57 cents per capsule. Although these prices do change periodically, this decline can have a huge impact on Medicare Set-Aside allocations. Should you have additional questions or need further information, please do not hesitate to contact NuQuest.